Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (375)	3/7/2003 5:30:13 PM
From: Icebrg	Read Replies (1) of 631

>> Genentech Announces March 21 Webcast Discussion of Data Presented at the American Academy of Dermatology Friday March 7, 4:39 pm ET>> Indicating that they are happy with the results. There seems to be a lot of enthusiasm building for the new biologic agents aimed at treating psoriasis. There will however be a number of different treatment options on offer. Perhaps a good thing it patients and doctors don't want to be stuck with one particular set of side-effects. But there is also another thing that concerns me. And that is treatment cost. I saw a report stating that the estimated costs for a year's treatment with Amevive could vary between 8.000 USD (one IV course per year) to 24.000 USD (two IM courses in a year). As I understand it most of the current treatment options are low-cost using generic drugs. Message 18653655 Is the US health system ready and able to start absorbing this kind of cost escalation. I suppose the benefits of drugs like Amevive, Raptiva (if approved), Enbrel and Remicade will only be enjoyed by those who are members of a company-sponsored health plan. Or are there also other ways of getting the benefit from these new drugs? Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next